Editorial Team It’s early 2026 and Sarah, the CEO of NeuroFlow, is in a tough spot. Her startup’s digital therapeutic for chronic migraines, a wearable and an app that deliver personalized neurofeedback, is technically a success. They have seed funding, they’ve got good efficacy data from a pilot study with Mass General, and they’re ready for a Series A round. The problem? Investors won’t bite without proof of scalability and a clear path to getting paid for it. With the Disrupt 2026 conference coming up fast in San Francisco, the event feels like a final exam for the company. NeuroFlow, like the rest of the healthcare tech world, had to figure out how to survive at the messy intersection of new tech, old regulations, and a skeptical market.
Key Takeaways
- The DTx market is set to explode, with projections hitting over $20 billion globally by 2028, mostly because regulators are finally creating clear rules and the clinical evidence is getting too strong to ignore.
- For a DTx to actually get used, it needs solid clinical proof it works, a green light from regulators like the FDA, and a way to get paid by insurance companies and government payers.
- AI and machine learning are making DTx smarter, personalizing the therapy and predicting patient needs, which directly leads to interventions that work better and improve patient health.
- If you’re pitching at a big tech conference like Disrupt 2026, you have to show exactly how you save money or improve care, back it up with real-world data, and have a plan for dealing with the messy American healthcare system.
- If people don’t trust you with their data or if only the rich can afford your DTx, you’re going to fail. Data privacy and equitable access aren’t optional for long-term survival.
“With an average wait of about seven years for complex surgery, which involves several specialities, delayed treatment means some women require a hysterectomy, like Colleen at 41.”
The Challenge of Validation: From Pilot to Payer
Sarah was sure her product worked. NeuroFlow’s MedRxiv pre-print showed their pilot cut migraine days by 35% over 12 weeks, that’s on par with some drugs, but without the side effects. “The science is solid,” she kept saying, “but the market sees software, not medicine.” That perception gap was the entire problem. Investors, especially the ones who actually knew healthcare, needed more than just efficacy data. They wanted a clear plan for getting doctors to use it and a reliable way to make money, a huge ask in the fractured US healthcare system for any new medical innovation.
Dr. Evelyn Reed, a VC at Sequoia who specializes in digital health, said the same thing to Reuters recently. “We’re past the era of ‘cool tech’ in healthcare,” she said. “Today, we fund solutions that show they work in the real world, have a solid clinical reason to exist, and a reimbursement strategy that isn’t just a fantasy.” You need all three to scale. Right now, NeuroFlow had the clinical part down, but its real-world evidence was thin and the reimbursement plan was just a sketch on a whiteboard. Sarah’s pitch at Disrupt 2026 had to nail those last two points, hard.
Working through the Regulatory Labyrinth: FDA and Beyond
To their credit, NeuroFlow had been smart about regulations from day one. They worked with the FDA inside the SaMD (Software as a Medical Device) framework and, in late 2025, got De Novo classification for their software. That wasn’t just a pat on the back. It was a huge differentiator that legitimized their clinical claims. So many other digital health apps just call themselves “wellness tools” to stay in a regulatory grey area, but doing that means doctors can’t prescribe them and insurance won’t pay for them.
The FDA getting its act together on digital therapeutics has definitely helped companies like NeuroFlow. A recent Pew Research Center report showed that 68% of Americans trust FDA-approved devices, so that stamp of approval was a key part of Sarah’s pitch. But FDA clearance doesn’t mean doctors will actually use it. They need to see how it fits into their workflow, and patients have to actually use the thing. This is why good UX and easy clinical integration are so important. NeuroFlow spent a ton on making their app intuitive and building reporting features that a patient could just send to their neurologist, trying to make life easier for everyone involved.
The Reimbursement Hurdle: A Payer’s Perspective
At a Disrupt pre-conference event, Sarah found herself talking to David Chen, a senior director from a big national insurance company. She jumped right in, hitting the main points: the migraine reduction data, the FDA De Novo status, and how NeuroFlow could cut down on expensive ER visits and opioid use. Chen was listening, but his questions were all business. “What’s your CPT code strategy? How are you keeping users engaged after the first month? And how will you prove long-term cost savings, not just that it works clinically?”
These were the exact questions that haunted Sarah. Some DTx products can use existing CPT codes for remote therapeutic monitoring, but it’s often a messy billing process that limits how much you get paid. NeuroFlow was trying to get its own unique CPT code, but that takes forever and there are no guarantees. To keep people using the app, they’d built in some gamification and used AI to predict when a user was about to drop off and send a personalized nudge. “We’re building a real-world evidence registry,” Sarah told Chen, “to track patient outcomes and healthcare costs for at least two years after they start. This gives payers the hard data they need on long-term value.” So many startups skip this step, but you can’t convince a CFO-minded payer without it. Yes, the Associated Press cited a report that the DTx market could pass $20 billion globally by 2028, but that number is pure fantasy if companies can’t figure out how to get paid.
Disrupt 2026: The Pitch and the Pivot
When it was time to pitch on the Moscone Center stage, Sarah didn’t start with the tech. She started with a story about a real migraine sufferer, making the pain of the condition feel immediate. Then she positioned NeuroFlow as a lifeline. She walked them through the clinical data and the FDA clearance, but the real kicker was when she announced pilot programs with several large employer health plans in California, including one in Sacramento. This wasn’t just a hypothetical. It was actual market traction.
Her presentation framed NeuroFlow as a solution to real problems in the healthcare system: it could help prevent physician burnout with remote monitoring, give patients self-management tools, and in the end bring down costs. She directly answered the kinds of questions Chen had asked, explaining their adherence strategy and their plan for proving long-term economic value. During the Q&A, a VC grilled her on data privacy. Sarah was ready, detailing their HIPAA-compliant architecture, end-to-end encryption, and how they followed global standards like GDPR to earn patient trust.
The Future is Now: Integration and Personalization
The pitch worked. Multiple investors cornered Sarah right after she got off stage, and even David Chen, the insurance exec, wanted a follow-up meeting, a very good sign. NeuroFlow’s win at Disrupt 2026 came from having a complete strategy that actually confronted the real-world problems of getting a digital therapeutic to market.
You could see the same pattern across Disrupt 2026. The companies getting all the buzz were the ones talking about AI-driven personalization, integration with EHRs, and concrete reimbursement plans. The day of the standalone health app is over. Now it’s all about fitting into the larger health system. Dr. Reed from Sequoia said it best in a panel later: “The next wave of medical innovation is about continuous patient support, using smart, personalized tools that fit into daily life and are treated like real medicine.” It’s a clear sign the digital therapeutics market is finally growing up.
NeuroFlow’s story is a perfect example of what it takes to make it in health tech right now. You can have the best engineers in the world, but if you don’t understand clinical workflows, the regulatory minefield, and the economics of healthcare, you’re dead on arrival. For any startup trying to break into this field, getting that early regulatory sign-off, building a mountain of clinical evidence, and making deals with payers aren’t just good ideas, they’re the only way to survive.
What are digital therapeutics (DTx)?
They’re therapies delivered through software to treat a medical condition. Unlike a random wellness app, a DTx has been clinically proven to work, is usually regulated as a medical device, and often needs to be prescribed by a doctor.
How do digital therapeutics get FDA approval?
They go through the same FDA pathways as medical devices, like the 510(k), De Novo, or PMA routes. Which path you take depends on the risk and novelty of the software, but in every case, you have to submit clinical data proving it’s safe and that it actually works.
What is the biggest challenge for digital therapeutics adoption?
Getting paid. By far the biggest hurdle is convincing insurance companies to cover the cost. You can have amazing clinical results, but if you can’t get on formularies and get decent reimbursement rates, your company won’t survive and patients won’t get access.
Can digital therapeutics replace traditional medicine?
No, they’re designed to work with traditional medicine, not replace it. Think of a DTx as another tool in the toolbox, something that works alongside drugs or other therapies to help manage a disease, often through patient education or changing behavior.
What role does AI play in the future of healthcare tech?
AI is what makes these new tools personal. It can tailor a treatment plan to one person, predict who might be at risk for a relapse, help with diagnostics, and keep patients engaged. With AI, a digital therapeutic can adapt and respond to a specific user, making it much more effective.
